<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064649</url>
  </required_header>
  <id_info>
    <org_study_id>MIST (terminated)</org_study_id>
    <secondary_id>5U01DK060817</secondary_id>
    <nct_id>NCT00064649</nct_id>
  </id_info>
  <brief_title>Minimally Invasive Surgical Therapy for BPH</brief_title>
  <acronym>MIST</acronym>
  <official_title>Minimally Invasive Surgical Therapy Consortium for Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Diagnostic Ultrasound</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Urologix</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi-Synthelabo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this randomized clinical trial is to determine the efficacy and&#xD;
      safety of three treatments for benign prostatic hyperplasia (BPH): transurethral needle&#xD;
      ablation (TUNA), transurethral microwave therapy (TUMT), and medical therapy with alfuzosin&#xD;
      and finasteride.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to recruit required sample size.&#xD;
  </why_stopped>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transurethral Needle Ablation (TUNA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transurethral Microwave Thermotherapy (TUMT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transurethral Microwave Thermotherapy (TUMT)</intervention_name>
    <description>type of minimally invasive surgical therapy for BPH</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transurethral Needle Ablation (TUNA) Therapy</intervention_name>
    <description>type of minimally invasive surgical therapy for BPH</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finasteride and Alfuzosin</intervention_name>
    <description>finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion&#xD;
&#xD;
          -  Patient signed informed consent prior to the performance of any study procedures or&#xD;
             discontinuation of any exclusionary medications.&#xD;
&#xD;
          -  Male at least 50 years of age.&#xD;
&#xD;
          -  AUA symptom severity score &gt;= 10.&#xD;
&#xD;
          -  Voided volume &gt;= 100 ml.&#xD;
&#xD;
          -  Post-void residual &lt; 350 ml.&#xD;
&#xD;
          -  Prostatic length 30-50 mm by cystoscopy (from bladder neck to verumontanum) or 35-60&#xD;
             mm by TRUS (from bladder neck to apex).&#xD;
&#xD;
          -  Prostate volume 25-100 cc by TRUS.&#xD;
&#xD;
          -  Prostate transverse diameter 34-80 mm.&#xD;
&#xD;
          -  Patient able to complete the study protocol in the opinion of the investigator.&#xD;
&#xD;
        Exclusion&#xD;
&#xD;
          -  Any prior surgical intervention for BPH.&#xD;
&#xD;
          -  Enrolled in another treatment trial for any disease within the past 30 days.&#xD;
&#xD;
          -  Previously failed to respond to combination therapy with an alpha blocker and a&#xD;
             5-alpha reductase inhibitor.&#xD;
&#xD;
          -  Previous hypersensitivity, idiosyncrasy, or clinically suspected drug reaction to&#xD;
             alfuzosin or finasteride.&#xD;
&#xD;
          -  On alpha-blocker within the past month.&#xD;
&#xD;
          -  On a 5-alpha reductase inhibitor within the past 4 months.&#xD;
&#xD;
          -  On phenylephrine, pseudoephedrine, imipramine, an anticholinergic or cholinergic&#xD;
             medication within the past 2 weeks.&#xD;
&#xD;
          -  On estrogen, androgen, any drug producing androgen suppression, or anabolic steroids&#xD;
             within the past 4 months.&#xD;
&#xD;
          -  Bleeding disorder or taking anticoagulation medication unless patient is able to be&#xD;
             off anti-platelet medication for at least 10 days prior to MIST treatment.&#xD;
&#xD;
          -  Clinically significant renal or hepatic impairment as determined by abnormal&#xD;
             creatinine or AST levels (i.e., creatinine &gt; 2.0 mg/dL or AST &gt; 1.5 times the upper&#xD;
             limit of institutional norms).&#xD;
&#xD;
          -  Serum prostate specific antigen level &gt; 10 ng/ml.&#xD;
&#xD;
          -  Active urinary tract infection as determined by positive culture, bacterial&#xD;
             prostatitis within the past year documented by positive culture, or two documented&#xD;
             urinary tract infections of any type in the past year (UTI defined as &gt; 100,000&#xD;
             colonies per ml urine from midstream clean catch or catheterized specimen).&#xD;
&#xD;
          -  Biopsy of the prostate within the past 6 weeks.&#xD;
&#xD;
          -  Daily use of a pad or device for incontinence required or International Continence&#xD;
             Society male incontinence symptoms score &gt;= 13.&#xD;
&#xD;
          -  Episode of unstable angina pectoris, myocardial infarction, transient ischemic attack,&#xD;
             or cerebrovascular accident (stroke) within the past 6 months, or peripheral arterial&#xD;
             disease with intermittent claudication or Leriches syndrome.&#xD;
&#xD;
          -  Orthostatic hypotension defined as drop of &gt; 20 mm Hg in supine to standing SPB or a&#xD;
             drop of &gt; 10 mm Hg in supine to standing DBP, in either standing BP reading, or the&#xD;
             development of symptoms of postural hypotension (e.g., dizzy or light-headed).&#xD;
&#xD;
          -  Penile prosthesis.&#xD;
&#xD;
          -  Artificial urinary sphincter or any implant, metallic or nonmetallic, within 1.5&#xD;
             inches of the prostatic urethra.&#xD;
&#xD;
          -  History or current evidence of carcinoma of the prostate or bladder, pelvic radiation&#xD;
             or surgery, or urethral stricture that requires dilation to pass a flexible&#xD;
             cystoscope.&#xD;
&#xD;
          -  Non-symmetric median prostatic lobe enlargement or a prominent obstructing &quot;ball&#xD;
             valve&quot; prostatic lobe as determined by cystoscopy.&#xD;
&#xD;
          -  Known primary neurologic conditions such as multiple sclerosis or Parkinson's disease,&#xD;
             any component of an implantable neurostimulation system, or other neurological&#xD;
             diseases known to affect bladder function.&#xD;
&#xD;
          -  Cancer that is not considered cured, except basal cell or squamous cell carcinoma of&#xD;
             the skin (cured defined as no evidence of cancer within the past 5 years).&#xD;
&#xD;
          -  Defibrillator or pacemaker that cannot be deactivated during MIST.&#xD;
&#xD;
          -  Neurogenic decompensated or atonic bladder in the opinion of the investigator.&#xD;
&#xD;
          -  Patient has an interest in future fertility.&#xD;
&#xD;
          -  Previous rectal surgery other than hemorrhoidectomy.&#xD;
&#xD;
          -  Any serious medical condition likely to impede successful completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reginald Bruskewitz, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison, WI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>July 10, 2003</study_first_submitted>
  <study_first_submitted_qc>July 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2003</study_first_posted>
  <last_update_submitted>January 12, 2010</last_update_submitted>
  <last_update_submitted_qc>January 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Kathryn Hirst/Coordinating Center Principal Investigator</name_title>
    <organization>George Washington University Biostatistics Center</organization>
  </responsible_party>
  <keyword>prostate</keyword>
  <keyword>benign disease</keyword>
  <keyword>TUNA</keyword>
  <keyword>TUMT</keyword>
  <keyword>medical therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Finasteride</mesh_term>
    <mesh_term>Alfuzosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

